Seres Therapeutics Inc represents values of innovation, dedication, and collaboration in the field of microbiome therapeutics. The company is committed to developing cutting-edge therapies to treat serious diseases by harnessing the potential of the human microbiome. With a focus on scientific rigor and breakthrough research, Seres Therapeutics aims to improve the lives of patients through transformative healthcare solutions. The company's corporate philosophy emphasizes patient-centricity, scientific excellence, and a commitment to advancing the understanding and application of microbiome science. Seres Therapeutics Inc strives to be a leader in the microbiome therapeutics space, driving positive changes in healthcare through its pioneering approach.

Seres Therapeutics Inc is primarily present in the United States.

Seres Therapeutics Inc, a leading biotechnology company, has achieved significant milestones in its journey. The company has successfully advanced its innovative microbiome therapies, helping revolutionize the treatment of infectious diseases. Among the notable achievements, Seres Therapeutics Inc gained FDA approval for its groundbreaking therapy, SER-109, to address recurrent Clostridioides difficile infection. Additionally, the company has expanded its pipeline, conducting clinical trials for various indications like ulcerative colitis and inflammatory bowel disease. Seres Therapeutics Inc continues to demonstrate its commitment to scientific excellence and pioneering breakthroughs in microbiome therapeutics, fulfilling its mission to improve patients' lives with innovative treatment options.

Seres Therapeutics Inc is a biopharmaceutical company specializing in microbiome therapeutics. Founded in 2010, the company aims to develop innovative treatments by harnessing the power of the human microbiome, which is composed of trillions of microorganisms. Seres Therapeutics Inc has made significant strides in the field of microbiome-based therapies, pioneering breakthrough treatments for a range of diseases including Clostridium difficile infection, inflammatory bowel diseases, and metabolic disorders. With a mission to revolutionize the way diseases are treated, Seres Therapeutics Inc continues to advance its research and development efforts, relentlessly striving to improve patient outcomes through microbiome-based interventions.

The main competitors of Seres Therapeutics Inc in the market include companies such as Rebiotix Inc, Synthetic Biologics Inc, Evelo Biosciences Inc, and Ferring Pharmaceuticals Inc.

Seres Therapeutics Inc is primarily active in the field of biotechnology and pharmaceuticals.

The business model of Seres Therapeutics Inc is focused on developing microbiome-based therapeutics to treat serious diseases. Seres Therapeutics harnesses the power of the human microbiome to develop novel, precision therapeutics that restore the underlying biology of disease. By leveraging its proprietary microbiome therapeutics platform, the company aims to create innovative therapies targeting various conditions, such as inflammatory bowel disease, Clostridium difficile infection, and gastrointestinal diseases. Seres Therapeutics collaborates with healthcare providers, academic institutions, and industry partners to advance its research and bring microbiome-based therapies to patients in need.

P/E odnos Seres Therapeutics iznosi -0,72.

KUV kompanije Seres Therapeutics iznosi 0.

AlleAktien kvalitativni skor za Seres Therapeutics je 6/10.

Prihod trenutno ne može biti izračunat za Seres Therapeutics.

Dobit očekivana Seres Therapeutics je -151,04 mil. USD.

Seres Therapeutics Inc is a biopharmaceutical company that focuses on the research and development of microbiome-based therapies. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics' business model is based on the discovery and development of therapies targeting the human body's microbiome. The microbiome includes all microorganisms such as bacteria, viruses, and fungi that live on and in our bodies. Seres Therapeutics is working to explore the role of the microbiome in various diseases in order to develop new and innovative therapies. The company has three main divisions: 1. Therapeutics Development Seres Therapeutics develops microbiome-based therapeutics for the treatment of various diseases, including inflammatory bowel diseases, recurrent Clostridium difficile infections, and cancer. The company's first approved product is SER-109, an orally administered therapy for recurrent Clostridium difficile infections. SER-109 consists of a mixture of bacterial strains specifically selected from healthy donor stool samples to restore balance in the gut. 2. Research and Development Seres Therapeutics heavily invests in microbiome research and the development of new therapies. The company has gained a comprehensive understanding of the functions of the microbiome and continuously works to expand this knowledge. Seres Therapeutics has also established partnerships with leading academic institutions and pharmaceutical companies worldwide to advance microbiome research and development. 3. Diagnostics Seres Therapeutics has also invested in the development of diagnostic platforms that enable comprehensive analysis of the microbiome. The company's diagnostic platforms include sequencing technologies and bioinformatic tools for analyzing microbiome composition. Seres Therapeutics' diagnostic platforms are suitable for both research and clinical applications and can contribute to accelerating the development of new microbiome-based therapies. Overall, Seres Therapeutics' business model is focused on the research and development of innovative microbiome-based therapeutics and diagnostic platforms. The company has already brought its first product to market and is working hard to develop further treatment options for patients. With a comprehensive understanding of the microbiome and partnerships in research and development, Seres Therapeutics is well-positioned to shape the future of microbiome therapies.

Seres Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Seres Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Seres Therapeutics je US81750R1023.

WKN od Seres Therapeutics je A14VXX.

Oznaka za praćenje akcija kompanije Seres Therapeutics je MCRB.

U poslednjih 12 meseci, Seres Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Seres Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Seres Therapeutics trenutno iznosi .

Seres Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Seres Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Seres Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Seres Therapeutics od 5. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 5. 10. 2024..

Isplata poslednje dividende izvršena je 5. 10. 2024..

U godini 2023 kompanija Seres Therapeutics je isplatila 0 USD kao dividende.

Dividende od Seres Therapeutics se isplaćuju u USD.